FY2027 EPS Estimates for aTyr Pharma Reduced by Analyst

Key Points

• Analysts at HC Wainwright reduced their FY2027 EPS estimate for aTyr Pharma from $0.38 to $0.34 per share, while maintaining a "Buy" rating and a target price of $35.00.
• Several investment firms have revised their ratings, with Wells Fargo increasing their price target from $17.00 to $25.00, while Wall Street Zen downgraded it from "hold" to "sell."
• The company's recent earnings report showed a loss of ($0.22) EPS for the quarter, missing the consensus estimate of ($0.18) EPS by ($0.04).

aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report) - Stock analysts at HC Wainwright cut their FY2027 EPS estimates for shares of aTyr Pharma in a research note issued to investors on Friday, August 8th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn $0.34 per share for the year, down from their prior estimate of $0.38. HC Wainwright currently has a "Buy" rating and a $35.00 target price on the stock. The consensus estimate for aTyr Pharma's current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for aTyr Pharma's FY2028 earnings at $0.46 EPS.

A number of other equities research analysts have also commented on the stock. Wells Fargo & Company upped their price objective on shares of aTyr Pharma from $17.00 to $25.00 and gave the company an "overweight" rating in a research note on Friday, June 20th. Wall Street Zen lowered shares of aTyr Pharma from a "hold" rating to a "sell" rating in a research note on Saturday. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, aTyr Pharma has a consensus rating of "Moderate Buy" and a consensus target price of $20.20.

aTyr Pharma Trading Up 1.1%

NASDAQ:ATYR opened at $5.30 on Monday. The firm's fifty day moving average is $5.34 and its 200-day moving average is $4.12. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.63 and a current ratio of 5.63. aTyr Pharma has a 52 week low of $1.67 and a 52 week high of $7.29. The firm has a market cap of $471.72 million, a P/E ratio of -6.62 and a beta of 0.94.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.04).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 Asset Management L.P. acquired a new position in aTyr Pharma during the fourth quarter worth $17,677,000. Octagon Capital Advisors LP raised its holdings in aTyr Pharma by 294.7% during the first quarter. Octagon Capital Advisors LP now owns 3,552,000 shares of the company's stock worth $10,727,000 after buying an additional 2,652,000 shares during the last quarter. Woodline Partners LP acquired a new position in aTyr Pharma during the fourth quarter worth $6,092,000. Alyeska Investment Group L.P. acquired a new position in aTyr Pharma during the fourth quarter worth $4,628,000. Finally, Millennium Management LLC raised its holdings in aTyr Pharma by 334.5% during the first quarter. Millennium Management LLC now owns 1,599,041 shares of the company's stock worth $4,829,000 after buying an additional 1,231,052 shares during the last quarter. 61.72% of the stock is owned by institutional investors.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.